Last updated on April 23, 2014 at 1:22 EDT

Tissue Regeneration Therapeutics Grants Exclusive U.S. License for PeriVascular Umbilical Cord Stem Cell Technology to PerkinElmer’s ViaCord(R) Cord Blood Banking Business.

October 28, 2011

The agreement includes a collaborative research initiative, which supports Tissue Regeneration Therapeutics’ international
leadership in the field of mesenchymal stem cell technology.

TORONTO, Oct. 28, 2011 /PRNewswire/ – J. E. Davies, President and CEO of Tissue Regeneration Therapeutics (TRT), announced today an exclusive licensing agreement with PerkinElmer’s
family cord blood banking business, ViaCord(R), which will now be able to offer families in the US
the ability to extract stem cells from the tissue surrounding the
vessels of the umbilical cord, a rich source of mesenchymal stem cells
(MSCs). The proprietary extraction method is enabled through TRT’s
human umbilical cord perivascular cell (HUCPVC) technology.

TRT first identified this important source of newborn stem cells, a
finding independently confirmed by international research groups. Since
these stem cells have many important potential applications in the
body, they may represent a valued medical option to ViaCord’s family
banking customers for a variety of diseases. TRT has shown that these
cells can produce all the tissues of the musculo-skeletal system e.g.
bone, cartilage, muscle, tendons and the dermis of the skin. These
cells also accelerate wound healing by stimulating the growth of new
blood vessels, and additionally possess unique immuno-regulatory
properties and may be used to treat immune and inflammatory diseases.

Families in Canada were the first in the world to have access, since
2006, to this umbilical cord tissue HUCPVC technology through a license
to CReATe Cord Blood Bank, who market the TRT technology as Peristem(TM), making both TRT and CreATe leaders in the worldwide stem cell
community. “Because of this agreement between ViaCord and TRT, ViaCord
can exclusively offer families in the US the ability to benefit from
TRT’s robust, and leading, internationally patented technology,” said
Bruce Berckmans, Vice President of Business Development for TRT.

The TRT technology will be offered in the US to expectant parents, by
ViaCord, as an important adjunct to their current cord cell banking
services. “The agreement between ViaCord and TRT further distinguishes
ViaCord’s leadership in the area of cord tissue stem cell banking by
providing our customers with exclusive access to this rich source of
MSCs from umbilical cord tissue,” said Morey Kraus, chief scientific
officer for ViaCord. This new capability is exclusive to ViaCord, the
only cord blood banking service in the US with licenses to patent
rights relating to the expansion of MSCs from cord tissue as well as
the extraction and expansion of MSCs from the tissue around the cord
vessels. Banking newborn cord tissue stem cells in addition to cord
blood stem cells provides the potential for a greater number and
variety of cells, increasing chances of potential success and benefit
from possible therapeutic applications.

The agreement also includes a collaborative research initiative, which
will focus on the therapeutic benefits and anti-inflammatory properties
of TRT’s mesenchymal stem cells. “ViaCord has established a leading
position in the study and identification of new uses for stem cell
treatments within the clinical setting, and is an ideal complement to
the robust scientific foundation that we, at TRT, have built in the MSC
field,” said Davies. The initiative is designed to generate results
that will provide a foundation for clinical studies of stem cell
applications for inflammatory joint diseases.

ViaCord family cord banking services currently offers expectant families the opportunity to
preserve their baby’s umbilical cord blood, and cord tissue cells, for
potential medical use by the child or a related family member. To date,
ViaCord has preserved the umbilical cord blood of more than 250,000

About Tissue Regeneration Therapeutics (TRT)
TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the
commercial development of their patented Human Umbilical Cord
PeriVascular Cell (HUCPVC) platform technology. TRT is the first company in the world to have
issued and allowed patents in both the USA and Europe for extraction of
these unique cells from umbilical cord tissue. TRT provides license
opportunities to collaborating partner companies in the family banking,
regenerative medicine and defense sectors. Additional information is
available at www.verypowerfulbiology.com.

About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The Company reported revenue of
approximately $1.7 billion in 2010, has about 6,200 employees serving
customers in more than 150 countries, and is a component of the S&P 500
Index. Additional information is available through 1 877 PKINYSE, or at

SOURCE Tissue Regeneration Therapeutics Inc.

Source: PR Newswire